NUWE
Nuwellis, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.78
+6.29%Year over year
Reported trailing growth
- Revenue
- +8.4%
- EBITDA
- +13.4%
- EBIT
- -28.2%
- EPS
- +93.6%
- Free cash flow
- -46.1%
- Operating cash flow
- -44.8%
Forward estimates
Based on analyst estimates
- Revenue
- -44.0%
- EBITDA
- +39.0%
- EPS
- +81.0%
Three-year CAGR
- Revenue
- -1.1%
- EBITDA
- +37.8%
- EBIT
- -1.1%
- Net income
- -56.9%
- EPS
- +90.9%
- Free cash flow
- -12.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026